203 träffarDigital passion

I år vill svenskarna checka av sina drömupplevelser31.3.2025 09:02:04 CEST | Mastercard | Pressmeddelande

I år jagar svenskarna upplevelser: 58 procent av svenskarna vill uppleva något stort under 2025, enligt en ny undersökning från Mastercard. En fjärdedel (24%) av svenskarna planerar att spendera över 10 000 kronor på rese- och turistrelaterade upplevelser i år Unga svenskar (generation Z) leder utvecklingen, där hälften planerar att checka av två eller fler upplevelser under 2025 Att skapa unika minnen, uppleva världen på nya sätt och dela upplevelser med sina nära och kära är några av de främsta anledningarna till att svenskarna väljer att prioritera upplevelser Resor och turism (88%), matrelaterade upplevelser (86%) och livemusik (78%) är de upplevelser som svenskarna ser mest fram emot under 2025
news aktuell GmbH

Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen24.3.2025 13:02:22 CET | news aktuell GmbH | Pressmeddelande

The first natural, responsible multi-generational skincare brand in Europe Princess Madeleine: “Weleda is the ideal partner for developing products that nurture and protect children's natural skin barrier. As a mother, I am mindful about the skincare products my family uses, making minLen a deeply personal project for me.” Weleda CEO Tina Müller: “At a time when even young children are reaching for their mother’s retinol cream, we are introducing an alternative the whole family can use without hesitation. We are honoured to have realised this important project with Madeleine.” First joint public appearance: 28 March 2025, Düsseldorf
World Childhood Foundation

Ending violence against children is possible15.11.2024 19:19:56 CET | World Childhood Foundation | Press Release

NEW YORK – States and key stakeholders from the United Nations System, academia, civil society, and survivors’ organizations identified on Thursday effective and sustainable actions to tackle violence against children. The high-level event held at the United Nations Headquarters, "From Commitment to Action," was co-hosted by World Childhood Foundation, the Permanent Mission of Sweden to the United Nations, and the Office of the Special Representative of the Secretary-General on Violence Against Children, with the participation of HRH Princess Madeleine of Sweden and Ms. Amina J. Mohammed, Deputy Secretary-General of the United Nations.
The Edelstam Foundation

LE JOURNALISTE DÉTENU ARBITRAIREMENT LE PLUS LONGTEMPS AU MONDE REÇOIT LE PRIX EDELSTAM11.11.2024 11:02:00 CET | The Edelstam Foundation | Press Release

Le Prix Edelstam 2024 est décerné à M. Dawit Isaak pour ses contributions exceptionnelles et son courage remarquable à défendre la liberté d'expression, ses convictions et les droits de l'homme. Le prix sera remis lors d'une cérémonie à la Maison de la Noblesse à Stockholm, en Suède, le 19 novembre 2024. Étant donné que Dawit Isaak est un prisonnier d'opinion et le journaliste détenu le plus longtemps au monde, il ne pourra pas être présent. Sa fille, Betlehem Isaak, recevra le prix en son nom.

VÄRLDENS LÄNGST GODTYCKLIGT FRIHETSBERÖVADE JOURNALIST FÅR EDELSTAMPRISET11.11.2024 11:02:00 CET | The Edelstam Foundation | Pressmeddelande

Edelstampriset 2024 tilldelas Dawit Isaak för hans enastående insatser och exceptionella mod i att stå upp för yttrandefriheten, sin övertygelse och försvaret av de mänskliga rättigheterna. Priset kommer att delas ut vid en ceremoni på Riddarhuset i Stockholm den 19 november 2024. Eftersom Dawit Isaak är samvetsfånge, och den journalist i världen som hållits fängslad längst, kan han inte närvara. Hans dotter, Betlehem Isaak, kommer att ta emot priset på hans vägnar.
news aktuell GmbH

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist22.10.2024 13:11:31 CEST | news aktuell GmbH | Pressmeddelande

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as pot
  • 1
  • 2
  • 3
  • 4
  • 5
  • Sista
  • >>
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye